Phaseline

Companies › Axter Therapeutics (Beijing)

Axter Therapeutics (Beijing): clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AXT-1003–Phase 1Non-Hodgkin Lymphoma; mCRPCMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06484985AXT-1003Phase 1Non-Hodgkin LymphomaOncologyMar 2027
NCT07897071AXT-1003Phase 1mCRPCOncologyAug 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.